ACOGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Alpha Cognition Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$8.50+0.31 (+3.79%)
Close on Oct 19, 2026
- Market cap
- $185.08M
- P/E (TTM)
- –
- Dividend yield
- –
Alpha Cognition Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Product, net | $6.04M | $3.50M | $2.53M | $2.33M | $1.58M | $346.93K | – | 99.2% | +283.2% |
| Licensing | $51.47K | $29.98K | $258.61K | $506.64K | $81.28K | $2.58M | – | 0.8% | -36.7% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| United States | – | $3.50M | – | – | – | $346.93K | – | – | – |
| China | – | $29.98K | – | – | – | $2.58M | – | – | – |
From the segment and revenue-disaggregation notes of Alpha Cognition's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.